[1]
Ferlay, J.; Steliarova-Foucher, E.; Lortet-Tieulent, J.; Rosso, S.; Coebergh, J.W.W.; Comber, H.; Forman, D.; Bray, F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur. J. Cancer, 2013, 49(6), 1374-1403.
[2]
Siegel, R.L. Miller. K.D.; Fedewa. S.A.; Ahnen. D.J.; Meester. R.G.S.; Barzi. A.; Jemal. A. Colorectal cancer statistics. CA Cancer J. Clin., 2017, 67(3), 177-193.
[3]
van Zijl, F.; Krupitza, G.; Mikulits, W. Initial steps of metastasis: Cell invasion and endothelial transmigration. Mutat. Res. Rev. Mutat. Res., 2011, 728(1), 23-34.
[4]
Jiang, W.G.; Sanders, A.J.; Katoh, M.; Ungefroren, H.; Gieseler, F.; Prince, M.; Thompson, S.; Zollo, M.; Spano, D.; Dhawan, P. Tissue invasion and metastasis: Molecular, biological and clinical perspectives. Semin. Cancer Biol., 2015, 35, S244-S275.
[5]
Mehner, C.; Hockla, A.; Miller, E.; Ran, S.; Radisky, D.C.; Radisky, E.S. Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Oncotarget, 2014, 5(9), 2736.
[6]
Bai, X.; Li, Y-y.; Zhang, H-y.; Wang, F.; He, H-l.; Yao, J-c.; Liu, L.; Li, S-S. Role of matrix metalloproteinase-9 in transforming growth factor-β1-induced epithelial–mesenchymal transition in esophageal squamous cell carcinoma. OncoTargets Ther., 2017, 10, 2837.
[7]
Liu, Z.; Li, L.; Yang, Z.; Luo, W.; Li, X.; Yang, H.; Yao, K.; Wu, B.; Fang, W. Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer, 2010, 10(1), 270.
[8]
Marečko, I.; Cvejić, D.; Šelemetjev, S.; Paskaš, S.; Tatić, S.; Paunović, I.; Savin, S. Enhanced activation of matrix metalloproteinase-9 correlates with the degree of papillary thyroid carcinoma infiltration. Croat. Med. J., 2014, 55(2), 128-137.
[9]
Salehabadi, H.; Khajeh, K.; Dabirmanesh, B.; Biglar, M.; Mohseni, S.; Amanlou, M. Surface plasmon resonance based biosensor for discovery of new matrix metalloproteinase-9 inhibitors. Sens. Actuators B Chem., 2018, 263, 143-150.
[10]
Ndinguri, M.W.; Bhowmick, M.; Tokmina-Roszyk, D.; Robichaud, T.K.; Fields, G.B. Peptide-based selective inhibitors of matrix metalloproteinase-mediated activities. Molecules, 2012, 17(12), 14230-14248.
[11]
Srivastava, P.; Tiwari, A. Critical role of computer simulations in drug discovery and development. Curr. Top. Med. Chem., 2017, 17(21), 2422-2432.
[12]
Ou-Yang, S-s.; Lu, J-y.; Kong, X-q.; Liang, Z-j.; Luo, C.; Jiang, H. Computational drug discovery. Acta Pharmacol. Sin., 2012, 33(9), 1131.
[13]
Leelananda, S.P.; Lindert, S. Computational methods in drug discovery. Beilstein J. Org. Chem., 2016, 12, 2694-2718.
[14]
Meng, X-Y.; Zhang, H-X.; Mezei, M.; Cui, M. Molecular docking: A powerful approach for structure-based drug discovery. Curr. Comput. Aided Drug Des., 2011, 7(2), 146-157.
[15]
Ferreira, L.; dos Santos, R.; Oliva, G.; Andricopulo, A. Molecular docking and structure-based drug design strategies. Molecules, 2015, 20(7), 13384.
[16]
Guedes, I.A.; de Magalhães, C.S.; Dardenne, L.E. Receptor–ligand molecular docking. Biophys. Rev., 2014, 6(1), 75-87.
[17]
Klebe, G. Virtual ligand screening: Strategies, perspectives and limitations. Drug Discov. Today, 2006, 11(13-14), 580-594.
[18]
David, L.; Nielsen, P.A.; Hedstrom, M.; Norden, B. Scope and limitation of ligand docking: Methods, scoring functions and protein targets. Curr. Comput. Aided Drug Des., 2005, 1(3), 275-306.
[19]
Peters, M.B.; Merz, K.M. Semiempirical comparative binding energy analysis (SE-COMBINE) of a series of trypsin inhibitors. . J. Chem. Theory Comput., 2006, 2(2), 383-399.
[20]
Ara, A.; Kadoya, R.; Ishimura, H.; Shimamura, K.; Sylte, I.; Kurita, N. Specific interactions between zinc metalloproteinase and its inhibitors: Ab initio fragment molecular orbital calculations. J. Mol. Graph. Model., 2017, 75, 277-286.
[21]
Irwin, J.J.; Sterling, T.; Mysinger, M.M.; Bolstad, E.S.; Coleman, R.G. ZINC: A free tool to discover chemistry for biology. J. Chem. Inf. Model., 2012, 52(7), 1757-1768.
[22]
Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem., 2009, 30(16), 2785-2791.
[23]
Wang, J.; Wang, W.; Kollman, P.A.; Case, D.A. Automatic atom type and bond type perception in molecular mechanical calculations. J. Mol. Graph. Model., 2006, 25(2), 247-260.
[24]
Abbasi, M.; Sadeghi-Aliabadi, H.; Hassanzadeh, F.; Amanlou, M. Prediction of dual agents as an activator of mutant p53 and inhibitor of Hsp90 by docking, molecular dynamic simulation and virtual screening. J. Mol. Graph. Model., 2015, 61(Suppl. C), 186-195.
[25]
Cosconati, S.; Forli, S.; Perryman, A.L.; Harris, R.; Goodsell, D.S.; Olson, A.J. Virtual screening with autodock: Theory and practice. Expert Opin. Drug Discov., 2010, 5(6), 597-607.
[26]
Morris, G.M.; Green, L.G.; Radić, Z.; Taylor, P.; Sharpless, K.B.; Olson, A.J.; Grynszpan, F. Automated docking with protein flexibility in the design of femtomolar “click chemistry” inhibitors of acetylcholinesterase. J. Chem. Inf. Model., 2013, 53(4), 898-906.
[27]
Shirgahi-Talari, F.; Bagherzadeh, K.; Golestanian, S.; Jarstfer, M.; Amanlou, M. Potent human telomerase inhibitors: molecular dynamic simulations, multiple pharmacophore-based virtual screening, and biochemical assays. J. Chem. Inf. Model., 2015, 55(12), 2596-2610.
[28]
Wolber, G.; Langer, T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J. Chem. Inf. Model., 2005, 45(1), 160-169.
[29]
Pronk, S.; Páll, S.; Schulz, R.; Larsson, P.; Bjelkmar, P.; Apostolov, R.; Shirts, M.R.; Smith, J.C.; Kasson, P.M.; van der Spoel, D.; Hess, B.; Lindahl, E. GROMACS 4.5: A high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics, 2013, 29(7), 845-854.
[30]
Schuttelkopf, A.W.; van Aalten, D.M.F. PRODRG: A tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D ., 2004, 60(8), 1355-1363.
[31]
Søndergaard, C.R.; Olsson, M.H.M.; Rostkowski, M.; Jensen, J.H. Improved treatment of ligands and coupling effects in empirical calculation and rationalization of pKa values. J. Chem. Theory Comput., 2011, 7(7), 2284-2295.
[32]
Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G.A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H.P.; Izmaylov, A.F.; Bloino, J.; Zheng, G.; Sonnenberg, J.L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery, J.A.; Peralta, J.E.; Ogliaro, F.; Bearpark, M.; Heyd, J.J.; Brothers, E.; Kudin, K.N.; Staroverov, V.N.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J.C.; Iyengar, S.S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J.M.; Klene, M.; Knox, J.E.; Cross, J.B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R.E.; Yazyev, O.; Austin, A.J.; Cammi, R.; Pomelli, C.; Ochterski, J.W.; Martin, R.L.; Morokuma, K.; Zakrzewski, V.G.; Voth, G.A.; Salvador, P.; Dannenberg, J.J.; Dapprich, S.; Daniels, A.D. Farkas; Foresman, J.B.; Ortiz, J.V.; Cioslowski, J.; Fox; D.J. Gaussian, Inc.: Wallingford, CT, 2009.
[33]
Makarewicz, T.; Kaźmierkiewicz, R. Molecular dynamics simulation by GROMACS using GUI plugin for PyMOL. J. Chem. Inf. Model., 2013, 53(5), 1229-1234.
[34]
Dennington, R.; Keith, T.A.; Millam, J.M. Semichem Inc., 2005.
[35]
Rao, S.N.; Head, M.S.; Kulkarni, A.; LaLonde, J.M. Validation studies of the site-directed docking program libdock. J. Chem. Inf. Model., 2007, 47(6), 2159-2171.
[36]
Koes, D.R.; Camacho, C.J. ZINCPharmer: Pharmacophore search of the ZINC database. Nucleic Acids Res., 2012, 40, W409-W414.
[37]
Yamamoto, D.; Takai, S.; Miyazaki, M. Prediction of interaction mode between a typical ACE inhibitor and MMP-9 active site. Biochem. Biophys. Res. Commun., 2007, 354(4), 981-984.
[38]
Eckhard, U.; Huesgen, P.F.; Schilling, O.; Bellac, C.L.; Butler, G.S.; Cox, J.H.; Dufour, A.; Goebeler, V.; Kappelhoff, R.; Keller, U.A.D.; Klein, T.; Lange, P.F.; Marino, G.; Morrison, C.J.; Prudova, A.; Rodriguez, D.; Starr, A.E.; Wang, Y.; Overall, C.M. Active site specificity profiling of the matrix metalloproteinase family: Proteomic identification of 4300 cleavage sites by nine MMPs explored with structural and synthetic peptide cleavage analyses. Matrix Biol., 2016, 49(Suppl. C), 37-60.
[39]
Ara, A.; Kadoya, R.; Ishimura, H.; Shimamura, K.; Sylte, I.; Kurita, N. Specific interactions between zinc metalloproteinase and its inhibitors: Ab initio fragment molecular orbital calculations. J. Mol. Graph. Model., 2017, 75(Suppl. C), 277-286.
38
3